Welcome to our dedicated page for Burcon Nutrascience news (Ticker: BRCNF), a resource for investors and traders seeking the latest updates and insights on Burcon Nutrascience stock.
Burcon NutraScience Corporation reports developments tied to plant-based protein ingredients for the food and beverage industry. Company updates cover commercialization of high-performance protein products such as Peazzaz®, FavaPro and Puratein®, production scale-up, customer adoption across beverage, nutrition and plant-based food applications, and work with manufacturing partners to support demand.
Recurring news also includes operating and financial results, convertible-debenture financing, shareholder voting matters, warrant amendments, board changes and other governance actions. Burcon's communications frequently reference its patent portfolio for proteins derived from pea, canola, soy, hemp, sunflower and other plant sources.
Burcon (OTCQB: BRCNF) announced that all matters at its 2026 special meeting of shareholders held February 20, 2026 were duly approved. Shareholders approved the Convertible Debenture Financing and an amendment to the expiry date of insider-held warrants.
Disinterested shareholder approval was obtained where required. The company filed detailed voting results on SEDAR+ and expects to close the Convertible Debenture Financing on or about February 24, 2026, according to the company.
Burcon (OTCQB: BRCNF, TSX: BU) reported fiscal Q3 results for the period ended December 31, 2025, with revenue of $739,000 (up ~1100% year-over-year) and nine-month revenue of $1.439 million (up ~325% YoY). Burcon closed a $1.25 million tranche of a $6.9 million private placement and drew a related-party $480,000 loan to bridge funding while scaling production at Galesburg.
Net loss for nine months was $10.7 million and cash was $1.3 million at quarter end; the company expects the final private placement tranche to close on or about February 24, 2026.
Burcon (OTCQB: BRCNF) will hold a special shareholders meeting on February 20, 2026 (virtual) to seek disinterested shareholder approval to amend certain insider warrants. The company is extending the expiry of outstanding warrants totaling 1,544,249 common shares to June 30, 2027.
The Board has already amended Non-insider Warrants (effective February 19, 2026). Amendments for insider-held warrants are subject to disinterested shareholder approval at the Meeting. Management says exercising warrants could provide cash to accelerate capacity expansion.
Burcon (OTCQB: BRCNF) will host an investor conference call and webcast on Wednesday, February 11, 2026 at 5:00 p.m. ET to discuss fiscal 2026 third quarter results for the period ended December 31, 2025.
A press release with the Company's financial results will be issued prior to the call; a webcast link and archived replay will be available on Burcon's website under Presentations.
Burcon (OTCQB: BRCNF, TSX: BU) said it increased its non-brokered private placement of convertible debentures to an aggregate principal amount of up to $6.9 million on January 9, 2026, citing strong investor demand. Insiders and manufacturing partner owners have committed a minimum of $5.0 million. The TSX granted conditional approval pending compliance, including receipt of disinterested shareholder approval. Management reaffirmed a revenue target of more than $10 million for calendar 2026.
Burcon (OTCQB: BRCNF) closed the first tranche of a non‑brokered private placement of convertible debentures for $1.25 million, part of an aggregate financing of up to $6.3 million. Insiders and manufacturing partner owners committed at least $5.0 million in principal. The financing is conditionally approved by the TSX and the final tranche requires disinterested shareholder approval expected after a special meeting on February 20, 2026. Each debenture carries 15% interest, 48‑month maturity, and is convertible at $1.60 per share (with pre‑funded warrant option). Proceeds will fund production scale‑up, infrastructure planning, general corporate purposes and repay a short‑term loan.
Burcon (OTCQB: BRCNF) issued a shareholder letter highlighting 2025 commercial progress and plans for 2026 growth. The company reports calendar 2025 revenue of $1–3 million, validated its patented protein technologies at full commercial scale, and is selling ingredients across pea, canola, and fava platforms. Management reaffirmed a 2026 revenue target of more than $10 million and described a near‑term financing expected to support customer onboarding, increase throughput, and strengthen the balance sheet.
Burcon cites a pipeline of 200+ customer projects, a strategic manufacturing partnership with RE ProMan LLC, and insider support for the financing as evidence of commercial momentum entering 2026.
Burcon (OTCQB: BRCNF) announced that company insiders have increased their commitment to participate in the previously announced non-brokered private placement of convertible debentures. The company had earlier disclosed a minimum insider participation of $2.0 million in principal.
Because insider interest has grown since the November 12, 2025 announcement, Burcon said the larger insider participation could necessitate disinterested shareholder approval, and the Offering's close will be extended beyond the original on-or-about November 28, 2025 date while final terms are negotiated and required regulatory approvals (including TSX approval) are sought.
Burcon (OTCQB: BRCNF) reported fiscal Q2 results for the period ended September 30, 2025, highlighting first commercial production and sales of Puratein C canola and FavaPro fava proteins and expanded production of its pea protein.
Financials: Q2 revenue was $357,000 and six‑month revenue was $699,000 (up 783% and 152% vs prior year). Net loss was $7.1M (or $0.56/share); net cash used in operations was $4.6M. Cash on hand was $1.8M with a negative working capital of $8.2M. Post‑period items include >$500,000 in commercial orders, a $0.7M short‑term loan and a $4M convertible debenture offering.
Burcon (OTCQB: BRCNF) announced a non-brokered private placement of unsecured convertible debentures for up to $4.0 million, with insiders committing at least $2.0 million. Each debenture is $1,000, bears 15% interest payable at maturity, matures in 48 months, and is convertible at $2.27 per share. The company may prepay or force conversion if the TSX VWAP exceeds $4.54 for 14 consecutive trading days. Proceeds will fund inventory, production capacity, general corporate purposes and repay a short-term loan. Closing is expected on or about November 28, 2025, subject to TSX approval.
Separately, Burcon drew a related-party unsecured $700,000 loan on November 7, 2025 at 12% interest with a $7,000 commitment fee; the loan matures on the earlier of four months or closing of the Offering.